Collegium Pharmaceutical issues 2026 financial guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LVS
9. LRCX
10. MRK

Go back to Collegium Pharmaceutical issues 2026 financial guidance

Collegium Provides 2026 Financial Guidance and Business Update

January 8, 2026 8:00 AM EST

Product Revenues, Net Expected in the Range of $805 Million to $825 Million

Jornay PM® Net Revenue Expected in the Range of $190 Million to $200 Million

Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million

STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update.

2025 was a year of record growth for Collegium and we are excited to begin 2026 with significant momentum for continued success,... More